Enavogliflozin
Chemical compound
Pharmaceutical compound
Enavogliflozin Other names DWP16001 ATC code Legal status
(2S ,3R ,4R ,5S ,6R )-2-[7-Chloro-6-[(4-cyclopropylphenyl)methyl]-2,3-dihydro-1-benzofuran-4-yl]-6-(hydroxymethyl)oxane-3,4,5-triol
CAS Number PubChem CID ChemSpider UNII ChEMBL Formula C 24 H 27 Cl O 6 Molar mass 446.92 g·mol−1 3D model (JSmol )
C1CC1C2=CC=C(C=C2)CC3=CC(=C4CCOC4=C3Cl)[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O
InChI=1S/C24H27ClO6/c25-19-15(9-12-1-3-13(4-2-12)14-5-6-14)10-17(16-7-8-30-23(16)19)24-22(29)21(28)20(27)18(11-26)31-24/h1-4,10,14,18,20-22,24,26-29H,5-9,11H2/t18-,20-,21+,22-,24+/m1/s1
Key:KORCWPOBTZTAFI-YVTYUBGGSA-N
Enavogliflozin (DWP16001 /GCC5694A ) is an experimental selective SLC5A2 and SGLT2 inhibitor developed to treat diabetes and obesity.[ 1] [ 2] [ 3] [ 4] [ 5]
References
^ Hwang, Jun Gi; Lee, SeungHwan; Huh, Wan; Han, Jumi; Oh, Jaeseong; Jang, In-Jin; Yu, Kyung-Sang (September 2022). "Dose-dependent glucosuria of DWP16001, a novel selective sodium–glucose cotransporter-2 inhibitor, in healthy subjects" . British Journal of Clinical Pharmacology . 88 (9): 4100–4110. doi :10.1111/bcp.15348 . PMID 35395697 .
^ Kim, Ju-Hyun; Kim, Dong Kyun; Choi, Won-Gu; Ji, Hye-Young; Choi, Ji-Soo; Song, Im-Sook; Lee, Sangkyu; Lee, Hye Suk (11 September 2020). "In Vitro Metabolism of DWP16001, a Novel Sodium-Glucose Cotransporter 2 Inhibitor, in Human and Animal Hepatocytes" . Pharmaceutics . 12 (9): 865. doi :10.3390/pharmaceutics12090865 . PMC 7558535 . PMID 32932946 .
^ Kim, Byungwook; Huh, Ki Young; Hwang, Jun Gi; Nah, JaeJin; Huh, Wan; Cho, Jae Min; Jang, In-Jin; Yu, Kyung-Sang; Kim, Yun; Lee, SeungHwan (April 2023). "Pharmacokinetic and pharmacodynamic interaction between DWP16001, an sodium–glucose cotransporter 2 inhibitor and metformin in healthy subjects". British Journal of Clinical Pharmacology . 89 (4): 1462–1470. doi :10.1111/bcp.15613 . PMID 36422809 . S2CID 253838705 .
^ Rhee, Beomseok; Mahbubur, Rahman Md; Jin, Changfan; Choi, Ji-Soo; Lim, Hyun-Woo; Huh, Wan; Park, Joon Seok; Han, Jumi; Kim, Sokho; Lee, Youngwon; Park, Jinho (December 2022). "Evaluation of safety and anti-obesity effects of DWP16001 in naturally obese dogs" . BMC Veterinary Research . 18 (1): 237. doi :10.1186/s12917-022-03324-2 . PMC 9214997 . PMID 35733159 .
^ Yoon, Sukyong; Park, Min Soo; Jin, Byung Hak; Shin, Hyobin; Na, Jaejin; Huh, Wan; Kim, Choon Ok (3 July 2023). "Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium-glucose cotransporter-2 inhibitor, with phentermine in healthy subjects". Expert Opinion on Drug Metabolism & Toxicology . 19 (7): 479–485. doi :10.1080/17425255.2023.2249397 . PMID 37593838 . S2CID 265846294 .
SGLT1 Tooltip Sodium-glucose transporter 1 SGLT2 Tooltip Sodium-glucose transporter 2 SGLT1 Tooltip Sodium-glucose transporter 1 & SGLT2 Tooltip Sodium-glucose transporter 2